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Abstract 
Caspases and their substrates are key mediators of apoptosis and strongly implicated in various physiological 
processes. As the STK family is involved in apoptosis, and STK3 is a recently identified caspase-6 substrate, we 
assessed the expression and cleavage of STK3 in murine peripheral organs and brain regions during the aging 
process. We also assessed caspase-3, -6, -7 and -8 expression and activity in order to delineate potential 
mechanism(s) underlying the generation of the STK3 fragments observed, and their relation to the apoptotic 
pathway. We demonstrate for the first time the cleavage of STK3 by caspase-7 and show that STK3 protein levels 
globally increase throughout the organism with age. In contrast, caspase-3, -6, -7 and -8 expression and activity 
vary significantly amongst the different organs analyzed suggesting differential effects of aging on the apoptotic 
mechanism and/or non-apoptotic functions of caspases throughout the organism. These results further our 
understanding of the role of caspases and their substrates in the normal aging process and highlight a potential role 
for STK3 in neurodegeneration. 
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1 Introduction 
Caspases are cysteinyl peptidases that are activated by proteolysis and dimerization. This leads to cleavage of their 
substrates and ultimately cell death through the programmed cell death pathway. The caspase family is essential not 
only for cell death, but also for immunity, neurogenesis, synaptic activity, cell proliferation and differentiation 
(D'Amelio, Cavallucci, and Cecconi 2010; Kuranaga and Miura 2007; Schwerk and Schulze-Osthoff 2003).  
Activation of caspases is observed in many physiological and pathological processes including Alzheimer disease, 
Huntington disease, stroke and aging (Broughton, Reutens, and Sobey 2009; Graham, Ehrnhoefer, and Hayden 
2011a; LeBlanc 2013; Lee and Kim 2006; Pattison et al. 2006; Snigdha et al. 2012). The expression levels and 
activity of caspases during the aging process is organ and tissue specific. For instance, in the cerebral cortex of 
Wistar rats, caspase-3 (CASP3) protein expression decreases with aging whereas caspase-8 (CASP8) increases 
from 12 months of age onwards (Shimohama, Tanino, and Fujimoto 2001). In contrast to the cortex, CASP3 
expression levels do not change in the skeletal muscle of aged Fischer 344/Brown Norway rats compared to their 
younger counterparts (Chung and Ng 2006). 
The serine/threonine kinase 3 (STK3), also known as STE-20-like kinase MST2 (MST2), is a 56 kDa protein in the 
germinal center kinase group II of the MAPK (mitogen-activated protein kinase) family and is involved in 
apoptosis, differentiation, and proliferative signalling (Heallen et al. 2011; Kim et al. 2010; Li et al. 2013; Liu, Wu, 
et al. 2012; Oh et al. 2009; Qin et al. 2013). This pathway is often referred to as the signalling pathway of its 
ortholog in Drosophilia melanogaster, the Hippo signalling pathway. The activation of STK3 leads to the 
phosphorylation of Mps Once kinase activator-like 1 (MOB1), Large tumor suppressor 1 and 2 (LATS1/2) and 
Yes-associated protein (YAP). This results in the cytoplasmic retention and degradation of YAP, inhibiting the 
latter from promoting the transcription of proliferative genes such as c-myc and cyclin E via the transcription factor 
Scalloped/TEAD. STK3 also mediates the phosphorylation of the FOXO transcription factor family leading to the 
transcription of proapoptotic genes such as FasL, Trail and PUMA (Liu, Wong, et al. 2012) (Fig. 1). 
The two main post-translational modifications known to regulate STK3 activity are phosphorylation and caspase-
mediated cleavage. STK3 can homodimerize or heterodimerize with its homolog STK4 (MST1) allowing its 
activation by autophosphorylation whereas the protein phosphatase 1 and 2A (PP1 and PP2A) inactivate it (Deng, 
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Pang, and Wang 2003). STK3 is also regulated by CASP3 cleavage, which results in the production of 34 kDa N-
terminal fragments (Deng, Pang, and Wang 2003; Lee et al. 1998). These fragments are resistant to 
dephosphorylation by protein phosphatases (Deng, Pang, and Wang 2003) and conserve kinase activity. We have 
recently shown that STK3 is a caspase-6 (CASP6) substrate (Riechers et al. 2016) and a multiple sequence 
alignment of STK3 demonstrates that the caspase cleavage sites V63EID and D319ELD are conserved down to C. 
elegans and A. gambia, respectively, suggesting important roles for the fragments generated. The caspase substrate 
STK4 is cleaved by CASP3, 6 and 7 (O'Neill, Matallanas, and Kolch 2005). 
The majority of the work on STK3 has been made during development. However, the increase of caspase activity 
and production of reactive oxygen species (ROS) in neurodegenerative diseases and during aging, suggest that the 
production of STK3 fragments may play a role in neurodegeneration (Merksamer et al. 2013; Patten et al. 2010; 
Zhang, Zhang, and Herman 2003; Graham, Ehrnhoefer, and Hayden 2011a). We have previously shown that in 
striatal cells expressing mutant huntingtin  the level of STK3 and its fragments are increased compared to controls 
(Riechers et al. 2016). 
In order to gain a better understanding of apoptotic mechanisms and the role of STK3 in aging throughout the 
organism, we characterized the mRNA, and protein expression of STK3 in the normal aging process in peripheral 
organs and brain regions of C57BL/6 male mice. Moreover, we assessed the expression and activity levels of 
CASP3, 6, 7 and 8 in order to further our understanding of the potential mechanism(s) underlying the in vivo 
generation of STK3 fragments and their relation to the programmed cell death pathway.  
2 Material and methods 
2.1 Animals 
Peripherals organs and brain regions were collected as described previously from C57BL/6 male mice and grouped 
according to age: 3-4 months, 12 months, 23-28 months and older than 30 months (Lessard-Beaudoin et al. 2015). 
The animal care and ethics committee of University of Sherbrooke approved the protocols for this study (protocols 
303-12 and 133-14B). The mice were anaesthetized (Isoflurane, Abbott) and euthanized by cervical dislocation. 
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The upper part of the cranium was removed, and the brain was collected. The cortex, cerebellum, striata and 
hippocampi were then dissected. In parallel, kidney, liver, heart and spleen were harvested. 
2.2 Western blot analyses 
Peripheral organs and brain regions were homogenized and sonicated in lysis buffer (0.32 mM Sucrose, 20 mM 
Tris pH 7.2, 1 mM MgCl2, 0.5 mM EDTA pH 7.2) using a cocktail of protease inhibitors (Roche), 4.2 mM 
PefaBloc SC (Roche) and 10 µM Z-VAD-fmk (Enzo Life Sciences) and clarified by centrifugation at 13,000 rpm. 
The protein concentration was determined using the BCA protein assay kit (Pierce). Protein lysates (50 µg) were 
separated on a 7.5% or 10% SDS-PAGE gel and transferred to a PVDF membrane (PerkinElmer). The membranes 
were probed with anti-STK3 (ab52641, Abcam, 1:1000), anti-CASP3 (9662, Cell signalling, 1:1000), anti-CASP6 
(9762, Cell signalling, 1:500), anti-CASP7 (9492, Cell signalling, 1:1000), anti-CASP8 (9746, Cell signalling, 
1:1000) or anti-actin (MAB1501, Millipore, 1:10000) antibodies. Peroxidase activity was detected and 
densitometric values were obtained with the Odyssey Fc imaging system (Mandel) using Luminata Crescendo 
Western HRP substrate (Millipore). Quantification of β-actin or Coomassie staining was used to standardize the 
amount of protein in each lane depending on the protein stability in each organ and densitometric values obtained 
with the Odyssey Fc imaging system (Mandel).  
2.3 Real-Time Quantitative RT-PCR 
Total RNA was extracted from peripheral organs and brain regions with the RNeasy mini kit (QIAGEN) and 
cDNAs were prepared using ProtoScript Reverse Transcriptase II (#M0368X, New England BioLabs). 
Quantification was done using Mx3005P QPCR Systems (Stratagene) with mouse-specific β-actin primers 
(forward 5’- ACGGCCAGGTCATCACTATTG-3’; reverse 5’-CAAGAAGGAAGGCTGGAAAAGA-3’), STK3 
primers (Forward 5’-AGGCCCTATGTCCAACAGTG-3’ and Reverse 5’-CCATCATGGGGTCTAGTGCT-3’), 
CASP3 Primers (Forward 5’-TGTCATCTCGCTCTGGTACG-3’ and reverse 5’-TCCCATAAATGACCCCTTCA-
3’), CASP6 primers( Forward 5’-TGGCTCCTGGTACATTCAGGAT-3’ and reverse 5’-
TCCGTGAACTCCAGGGAACT-3’) and CASP8 primers( Forward 5’-CCTAGACTGCAACCGAGAGG-3’ and 
reverse 5’-GCAGGCTCAAGTCATCTTCC-3’). Amplification of β-actin was used to standardize the amount of 
sample RNA in the reaction. Gene-expression levels were measured using MxPro QPCR Software (Stratagene). 
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2.4 Caspase cleavage assays 
Recombinant caspases were expressed, purified and characterized as described elsewhere (Boucher, Duclos, and 
Denault 2014). Caspases were diluted in a reaction buffer (100 mM Hepes pH 7.4, 200 mM NaCl, 0.2% CHAPS, 
2 mM EDTA, 20% glycerol) at a concentration of 2000 nM and serially diluted. Final concentrations used for each 
caspase in the assay were 0, 7.8, 15.6, 31.3, 62.5, 125, 250, 500, and 1000 nM. The diluted recombinant caspases 
and 50 µg of brain lysate were pre-heated separately at 37 °C for 30 min, then mixed and incubated for 90 min at 
37 °C. Immunoblotting was performed as described above. 
2.5 Caspase activity assays 
Murine tissues were homogenized as described above without caspases inhibitors and the lysates diluted with 
reaction buffer (100 mM Hepes pH 7.4, 200 mM NaCl, 0.2% CHAPS, 2 mM EDTA, 20% glycerol and 20% DTT). 
The activity of endogenous CASP3, 6 and 8 was measured in the lysates using the preferred fluorogenic substrates 
AcDEVD-AFC, AcVEID-AFC and AcIETD-AFC, respectively (Enzo Life sciences) at 37°C for 60 min. It is noted 
that AcDEVD-Afc is also the preferred substrate of CASP7, and that no small peptidic substrate is specific to a 
particular caspase (McStay, Salvesen, and Green 2008). The fluorescence generated was measured by the VICTOR 
X Multilabel Plate Readers spectrophotometer (PerkinElmer). 
2.6 Statistical analysis 
Student t test, one-way ANOVA and the post hoc Tukey’s multiple comparison tests were used for analysis 
between the age groups.The statistical significance was established at 0.05 (*, p<0.05; **, p<0.01; ***, p<0.001; 
****, p<0.0001). GraphPad Prism 6.0 software was used for all statistical analysis (GraphPad Software, La Jolla, 
CA).  
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3 Results 
3.1 Differential cleavage of STK3 by CASP3, 6 and 7 
As STK4 is differentially cleaved by CASP3, 6 and 7 producing fragments with specific functions, we assessed the 
cleavage of STK3 by these caspases (Song and Lee 2008). Murine brain lysate was incubated with active-site 
titrated recombinant CASP3, 6 or 7, and STK3 cleavage was assessed. As expected, CASP3 and CASP6 cleave 
STK3 (Riechers et al. 2016; Lee et al. 2001). However, we also observed cleavage by CASP7 and noted that the 
caspases do not cleave STK3 with the same efficacy and do not produce the same fragment sizes. A higher 
concentration of CASP6 or 7 is required to cleave STK3 and generate the 34 kDa fragment when compared to 
CASP3. Interestingly, CASP6 is the only caspase that generates the 39 kDa STK3 fragment (Fig. 2). 
3.2 Region specific alterations in STK3 expression with aging in peripheral organs 
As the STK family is involved in multiple physiological processes, we assessed the mRNA and protein expression 
of STK3 and its fragments during the aging process. In the heart, a significant decrease in STK3 mRNA expression 
is observed by >30 months. In contrast, while there is a significant decrease in STK3 mRNA in the kidney at 12 
months of age, it then increases after 23-28 months (Fig. 3).  No significant difference in STK3 mRNA expression 
is observed with aging in the liver (ANOVA test).  However, the mRNA expression decreases significantly (43%) 
at 23-28 months of age in the liver (t test). In contrast to the heart and the kidney, STK3 mRNA expression level 
increases significantly (47%) in the spleen with aging till 23-28 months of age (Fig. 3).  
Overall, no significant change in STK3 protein expression levels is observed in the liver with aging (ANOVA). 
However, comparing the groups using t-test shows that STK3 FL protein levels decrease initially from 3 to 12 
months of age then increase at >30 months of age when compared to the 12 months values (Fig. 4A). The STK3 
39 kDa fragment expression levels in the liver also decrease at 12 months of age whereas the 34 kDa STK3 
fragment expression increases by 76% at >30 months of age when compared to 3 and 12 months age-group (Fig. 
4A).  In the kidney, a 3-fold increase is observed for the STK3 39 kDa fragment expression after the age of 12 
months (Fig. 4B).  While no significant variation in STK3 protein expression is observed in the heart, a positive 
correlation is observed in the STK3 34 kDa fragment with age (Fig. 4C). No significant variation in STK3 FL 
protein expression level is observed in the spleen, however a 2 to 3-fold increase is observed in STK3 39 kDa and 
34 kDa fragments suggesting an increase in STK3 cleavage occurs with age in the spleen (Fig. 4D).   
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3.3 Region-specific variations in STK3 expression in the brain with aging  
STK3 mRNA expression increases by 68% at 12 months of age in the cortex then decreases after 23 months of age. 
Hippocampal STK3 mRNA expression increases up to 23-28 months of age then decreases at >30 months of age. 
In the striatum, the mRNA expression levels of STK3 increase with aging (76%). In the cerebellum, no age 
dependent effects are observed (Fig. 5).  
In the cortex and the cerebellum, both the STK3 FL and the 34 kDa fragment forms increase significantly during 
the aging process (Fig. 6A-B). In contrast to other brain regions, no significant variation in the STK3 protein 
expression is observed in the striatum with age. However, a positive correlation is observed for the STK3 34 kDa 
fragment (Fig. 6C).  
3.4 Differential expression and activity of caspases in peripheral organs with aging 
In the liver, CASP6 and 8 mRNA expression levels decrease at 23-28 months of age. In contrast, an increase in 
mRNA expression of CASP3 and 6 is observed in the kidney after the age of 12 months. Similar to the liver, 
mRNA expression level of all caspases analyzed decreases at >30 months of age in the heart. No significant 
variation in any caspases is observed in the spleen with age (Fig. 7).   
With regards to caspase protein expression levels, cleaved (active) CASP3 and CASP6 proform expression 
decrease and no significant variation in CASP7 protein level is observed in the liver with the aging (Fig. 8A, 8B). 
In contrast, a ~5 fold increase of all protein forms of casp8 is observed in the liver after 3 months of age (Fig. 8D). 
In the kidney, the CASP3 zymogen (inactive form) significantly increases (54%) with age (Fig. 8E). A global 
increase in CASP6 and cleaved CASP8 expression levels is also observed in the kidney with aging (Fig. 8F, 8H). 
Interestingly, a 65-fold increase is observed in the CASP8 cleaved p43/41 form and a 26-fold increase is observed 
in cleaved CASP8 fragment in the kidney (Fig. 8H). Of note, and dissimilar to the other caspases, CASP7 
expression level tends to decrease with age in the kidney (Fig. 8G).  In contrast to the liver and the kidney, no 
significant variation is observed for CASP3 with aging in the heart and the spleen (Fig. 8G, 8J). However, in the 
heart, the CASP6 cleaved subunits (p20p10) increases by 99% and CASP7 proform decreases at 12 months of age 
(Fig. 8J, 8K). A 25-30-fold increase is also observed in CASP8 protein expression levels in the heart (Fig. 8L). 
Similar to the liver, CASP6 protein expression level decreases at 12 months of age in the spleen whereas all protein 
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forms of CASP8, CASP7 proform and p27 subunit demonstrate increased expression with age in the spleen (Fig. 
8N, 8O, 8P).  
An increase is observed in CASP3/7 activity in the liver with aging. No significant variation is observed in CASP6 
and 8 activities (Fig. 9A). In the kidney, CASP3/7 activity increase at 23-28 months of age while CASP8 activity 
shows a clear decrease at 12 months of age however than increases at >30 months of age (Fig. 9B). An increase in 
CASP6 and 8 activities is observed in the heart with aging whereas no significant variation is observed for 
CASP3/7 activity. Similarly, CASP8 activity increases with aging in the spleen (Fig. 9C-D). No significant 
variation is observed in CASP3/7 and 6 activities with age in the spleen (Fig. 9D). 
3.5 Variation of caspases expression and activities in brain regions with aging 
Decreased mRNA expression levels of all caspases analyzed is observed in the cortex with age. In the cerebellum, 
only a subtle increase in the mRNA expression of casp8 was observed at 23-28 months of age. Striatal mRNA 
expression levels of CASP6 and 8 increase with aging and hippocampal CASP6 mRNA expression levels increases 
while CASP3 mRNA decreases at an age of >30 months (Fig. 10). 
Striatal expression of the CASP6 zymogen decreases with age whereas the CASP6 cleaved p20p10 form increases 
suggesting an increase in CASP6 prodomain cleavage upon the aging process (Fig. 11A). Furthermore, a strong 
increase in all protein forms of CASP8 is observed in the striatum at 23-28 months of age (Proform: 85-fold, 
p43/41: 170-fold, p30: 28-fold, p18: 1684-fold, Fig. 11D). A global increase of caspase protein expression is also 
detected in the cortex with the exception of CASP7 which does not vary with age in that brain region (Fig. 11E-H). 
A 28 to 48-fold increase is observed in cortical CASP8 protein expression, a 30-fold increase in CASP6 p20p10 
and the CASP3 zymogen increases 43% with age (Fig. 11D, 11E,  11H). In the cerebellum, the CASP6 zymogen 
and cleaved p20p10 subunits also increase by 43% and 2-fold, respectively, with aging (Fig. 11J). Furthermore, a 
15-fold and a 61-fold increase are noted with age in the CASP8 zymogen and the cleaved p43/41 fragments, 
respectively (Fig. 11H).  Thus, similar to the other brain regions, the protein expression level of CASP6 and 8 
increase with age in the cerebellum contrary to CASP3, which protein expression decreases in this tissue (Fig. 11I, 
11J, 11L).  
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Despite the increase in CASP6 and 8 mRNA and protein expression levels with aging in the cerebellum, no 
variation in cerebellar CASP3/7, 6 or 8 activity was observed in our samples (Fig. 12A). However, in the cortex, 
increasing CASP6 protein levels correlated with an increase in its activity at 23-28 months of age. Surprisingly, 
although the cortical protein expression of CASP8 increases, a decrease is observed in its activity (Fig. 12B).  
4 Discussion 
We assessed cleavage of STK3 by CASP3, 6 and 7 and the expression levels of this substrate in several tissues 
during aging. We also assessed CASP3, 6, 7 and 8 expression and activity in peripheral organs and brain regions in 
the normal murine aging process (3 to 30 months of age). Overall, the pattern of mRNA and protein expression for 
CASP3, 6, 7 and 8, and their respective activities, vary strongly amongst the tissues tested and within the same 
organ, as observed in the different brain regions (Table 1). These results suggest a differential effect of aging on 
the apoptotic mechanisms and/or non-apoptotic functions of caspases. We demonstrate for the first time cleavage 
of STK3 by CASP7, which is often seen as redundant to CASP3, but which some studies show unique activities 
and substrate repertoire (Boucher, Blais, and Denault 2012; Lamkanfi et al. 2008; Slee, Adrain, and Martin 2001). 
Furthermore, we show the protein expression of STK3 (FL and proteolytic fragments) globally increases 
throughout the organism upon the aging process.   
4.1 Caspase-dependent processing of STK3 
STK4, an STK3 homolog, is also a known death substrate of CASP3, 6 and 7 with cleavage resulting in the 
production of  36 and 40 kDa fragments and STK3 has been previously identified as a CASP3 and 6 substrate 
(O'Neill, Matallanas, and Kolch 2005; Riechers et al. 2016). In our study, we demonstrate the cleavage of STK3 by 
all three caspases. However, whereas all caspases generate a 34 kDa STK3 fragment, CASP6 also generates a 39 
kDa fragment. The apoptotic functions of the STK4 36 kDa fragment are well described in the literature (Deng, 
Pang, and Wang 2003; Kilili and Kyriakis 2010; Kim et al. 2010; O'Neill et al. 2004; Qin et al. 2013) and some 
studies suggest that the 34 kDa STK3 fragment may have a similar role (Deng, Pang, and Wang 2003) . However, 
to our knowledge, the existence and the production of the STK3 39 kDa fragment by a caspase has not been 
previously described. It is possible that these two fragments of STK3, as described earlier for two fragments of 
STK4, may not have the same function in vivo. Indeed, the 40 kDa fragment of STK4 produced by CASP7 
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cleavage has been identified to selectively phosphorylate JNK and p38 while the 36 kDa fragment of STK4, 
produced by CASP3 cleavage, has been identified to selectively phosphorylate ERK (Song and Lee 2008). 
Additional studies are required to provide more precision regarding the STK3 caspase cleavage sites and the 
functions of the STK3 fragments produced by these cleavages events. 
4.2 STK3 expression level in peripheral organs 
In our studies, STK3 mRNA expression decreases in all peripheral organs except for the spleen where an increase 
is observed at 23-28 months of age. In contrast to the mRNA pattern, a global increase at the protein level in 
virtually all forms of STK3 is observed in these organs. Interestingly, the increase in fragment expression levels is 
not coupled with a decrease in the intact protein expression as may be expected due to cleavage. The increase in 
mRNA expression (and hence of the protein), in the spleen may compensate for the increased cleavage by caspases 
thereby stabilizing the FL form of STK3 in this organ. In the other peripheral organs, the stable or increasing level 
of the intact form may be a result of an increase in the half-life of the protein with age. For instance, the interaction 
of STK3 with phosphorylated RASSF2 which prevents STK3 degradation may be responsible for this stabilisation 
of the expression (Cooper et al. 2009).    
4.3 Caspases expression and processing of STK3 in the liver 
The decrease in CASP6 and 8 mRNA, and the decrease of caspase-3 and 6 protein expression in the liver with age 
corroborate the low cell death rate in this organ with aging observed in other studies (Suh 2002). The increase in 
the CASP8 active fragment may be more related to the non-apoptotic functions of the protease in the liver, such as 
cell proliferation and induction of inflammation (Ben Moshe et al. 2007). Surprisingly, we did not detect a 
corresponding increase in CASP8 activity in the liver. The absence of any significant variation in activity observed 
with aging in this organ may be a consequence of the presence of a natural inhibitor of casp8 such as c-flip or PI-9 
in the protein lysates (LeBlanc 2003). The increase observed in CASP3/7 activity at >30 months of age in the liver 
suggests that the increase in the 34 kDa fragment of STK3 observed may be due to CASP3 or CASP7 cleavage. It 
has been previously demonstrated that STK3 has predominantly anti-proliferative functions within hepatocytes (Jin 
et al. 2009; Qin et al. 2013). Therefore, the increase in STK3 cleavage in the liver may promote these anti-
proliferative functions of STK3 in the aging process rather than cell death per se.   
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4.4 Caspases expression and processing of STK3 in the kidney 
The trend increase in the 34 kDa fragment of STK3 present in the kidney may be a consequence of the increased 
activity of CASP3 observed in that organ. However, the increase in global expression of CASP6 in kidney suggests 
that it may also be responsible for the production of the 34 kDa fragment and suggests a role for this protease in the 
generation of the 39 kDa fragment, a fragment only produced by CASP6, and which is significantly increased with 
age in the kidney. However, no variation in activity is observed using the preferred CASP6 substrate. Therefore, it 
cannot be ruled out that a protease other than CASP6 cleaves STK3 to generate the 39 kDa STK3 fragments in the 
kidney. However, in addition to the presence of inhibitors (exogenous or endogenous) that can influence the result, 
the lack of specificity of the caspase peptidic substrates used in the activity assays that are available further requires 
caution in interpreting the results (McStay, Salvesen, and Green 2008). The increase in expression of STK3, and of 
all caspases tested (with exception of CASP7) in the kidney with aging, may reflect the increase in cell death 
observed previously with aging by TUNEL in the glomerular and corticotubular areas in the kidney (Lim et al. 
2012).  
4.5 Caspases expression and processing of STK3 in the heart 
In the heart, a decrease in CASP3, 6 and 8 mRNA expression levels is observed with aging. Interestingly, these 
differences were only noted when compared to the >30 months age-group. It is important to note that there are 
many metabolic changes observed between long lived mice compared to their younger counterparts that could be 
responsible for these results (Bartke and Westbrook 2012; Milman et al. 2014; Sherlock and Toogood 2007) as in 
general the normal life span of C57BL/6 mice is ~25 months. Moreover, these mice could be the result of a natural 
selection of a particular sub-group of individuals which may explain this decrease in caspases mRNA at >30 
months of age. In contrast to the mRNA expression levels, CASP6 and 8 protein expression and activity increases 
with aging, which corroborates the previously observed ~30% loss of cardiomyocytes with age (Sheydina, Riordon, 
and Boheler 2011). The increase in CASP6 activity observed in the heart may be responsible for the increase in 34 
kDa fragment of  STK3 production observed in our results. However, the increase in the STK3 fragment is not 
coupled with a decrease in the FL protein expression. As a decrease in STK3 mRNA level is observed with aging, 
STK3 may be a target for post-translational modifications that promote an increase in the half-life of the protein or 
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may interact with some proteins that slow down the degradation rate of STK3, such as RASSF2 (Cooper et al. 
2009).    
4.6 Caspases expression and processing of STK3 in the spleen 
Decreases in caspase-6 protein expression, and an increase in CASP7 and 8 protein expression and CASP8 activity, 
were observed in the spleen with aging. Of note, in vivo CASP6 active fragments are very difficult to detect by 
Western blotting, possibly due to short protein half-life. The decrease in CASP6 proform levels may be due to the 
processing and activation of the caspase or a more efficient degradation as we did not detect a decrease in gene 
expression in the spleen. Similar to our results, an increase in the activity of CASP8 and cell death has previously 
been observed in old C57BL/6 mice spleenocytes (Itzhaki et al. 2003). However, they also noted an increase in 
CASP3 activity between 2 and 15 months in old mice which we did not observed in our study. The difference 
between the ages selected (2 months of age considered in development in contrast to 3 months of age considered an 
adult), sex or strain of the mice used may be responsible for this difference. A trend increase is detected in all 
protein forms of STK3 in the spleen with aging. As no variation is observed in CASP3 expression or CASP3/7 
activity, the increase in STK3 fragment may be attributable to CASP6 and/or CASP7 as we did detect subtle 
processing of the zymogens in the spleen.  
4.7 Caspases expression and processing of STK3 in the brain 
Interestingly, the decrease in mRNA expression of STK3 and all caspases observed in the aging cortex does not 
reflect the variation at the protein level. All STK3 protein forms increase with age, which may be the result of a 
less efficient degradation of STK3, an increase of the protein half-life or, more generally, it may be the result of the 
decrease in proteasome activity previously observed in this brain region with aging (Baraibar and Friguet 2012). 
An increase in CASP6 and a decrease in CASP8 activities were observed in the cortex with aging while no 
variation was detected in CASP3/7 activity. Thus, the strong increase in cortical STK3 fragments may be the result 
of the cleavage of STK3 by CASP6. Interestingly, in contrast to peripheral tissue, no 39 kDa fragment is observed 
in any of the brain regions assessed which may suggest specific peripheral functions of this particular STK3 
fragment. 
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At the mRNA level, there is no variation observed in aging in any of the genes analyzed in the cerebellum 
except for CASP8 mRNA that increases. This increase in CASP8 mRNA levels is coupled with a strong increase in 
CASP8 protein expression. The absence of mRNA variation in CASP3 and 6 is not translated to the protein levels. 
A decrease in CASP3 and an increase in CASP6 protein expression are observed with aging in the cerebellum 
which suggest that CASP8, and potentially CASP6, may be a key caspase in neurodegeneration in the cerebellum 
with aging. A previous study has observed that while there is a stable number of Purkinje cells in the cerebellum 
with aging, there are some sections of the cerebellum, such as the anterior lobe, in which a loss of these cells is 
observed with aging (Andersen, Gundersen, and Pakkenberg 2003; Zhang, Zhu, and Hua 2010). As our analysis 
consisted of the entire cerebellum samples, this region-specific effect might be lost. Surprisingly, the variations at 
the protein level, even the strong increase in all forms of CASP8 protein levels, are not reflected in the caspase 
activity assay results. Our data suggest that the increase in the 34 kDa STK3 fragments observed in the cerebellum 
may be due to CASP6 as both the proform and the fragments increase with age in this brain region. We observe 
that both the FL and the STK3 34kDa fragments increase in the cerebellum with age supporting a role for apoptosis 
and caspases in the cerebellum with aging.  
The mRNA of CASP6 and 8 increase with age in the striatum. However, this variation is not reflected at the protein 
level for CASP6 which decreases with age. In contrast, all protein forms of CASP8 strongly increase with aging. 
Interestingly, between 23-28 months and >30 months of age, the CASP8 proform decreases by 86%, which 
correlates with the high amount of fragment present. Therefore, the decrease observed in the CASP8 zymogen at 
>30 months of age may be due to the processing and activation of CASP8. As no variation in CASP3, and a 
decrease in CASP6 protein expressions is observed in the striatum, the increase observed in 34 kDa STK3 fragment 
protein in our data may be more attributable to its processing by CASP7, which has a trend increase in expression 
level with aging, to a less efficient degradation of the protein or an increase of the protein half-life. Of note, no 
small peptide substrate is available specifically for CASP3, or 7 (McStay, Salvesen, and Green 2008). Therefore, 
we cannot confirm this hypothesis using activity assays. This increase in STK3 fragment expression correlates with 
the age-associated increase in apoptosis observed previously in the striatum of Wistar 2BAW rats (Ureshino et al. 
2010). Of note, we did not have enough samples to assess caspase activity in the striatum.   
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Finally, in the hippocampus, a decrease in CASP3 mRNA expression and an increase in the mRNA of CASP6 and 
STK3 are observed with aging. Of note, experiments in hippocampal primary cultures demonstrate that STK4, an 
homolog of STK3, is phosphorylated upon oxidative stress by c-abl leading to the stabilization of the protein 
expression of STK4 and the STK4-FOXO mediated cell death (Xiao et al. 2011).  Moreover, CASP6 is activated in 
neurodegenerative diseases and its activity in the hippocampal CA1 region is sufficient to induce neuronal 
degeneration, inflammation and age-related memory impairment (LeBlanc et al. 2014; Ramcharitar et al. 2013; 
Graham, Ehrnhoefer, and Hayden 2011b; Wang et al. 2015).  Thus, the increase in mRNA expression of STK3 and 
CASP6, a protease that cleaves STK3, highlight a possible role for STK3 in the neurodegeneration process in AD 
and potentially other neurodegenerative diseases. Unfortunately, we did not have enough hippocampal samples to 
assess protein expression of STK3 and caspases in this brain region. 
5 Conclusion 
Overall, our results demonstrate that the pattern of mRNA and/or  protein expression of CASP3, 6, 7 and 8 and 
their respective activity vary strongly throughout the organism and even amongst the same organ (as observed in 
the different brain regions) suggesting differential effects of aging on the apoptotic mechanism and/or non-
apoptotic functions of caspases. Moreover, STK3 expression, a newly identified substrate of CASP6 and 7, 
globally increases throughout the organism with the aging process. To our knowledge, this is the first time that the 
caspase expression and activity have been investigated as extensively throughout the entire organism during the 
aging process. This study provides important details regarding the pattern of expression and activity of the caspases 
and the caspase substrate STK3 throughout the entire organism upon a physiological stress that is the normal aging 
process.  These results further our understanding of the effect of aging on the organism without any pathological 
condition. 
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Figure 1. STK3 pathway. In the presence of oxidative stress, glutaredoxine (Grx1) and 
thioredoxine (Trx1) dissociates from STK3 promoting its activation by 
autophosphorylation. STK3 is also activated indirectly by the EGFR via PI3K/Akt 
signaling. The phosphorylation cascade promoted by STK3 activation results in a 
downregulation of proproliferative genes via the degradation of Yes-associated protein 
(YAP). The cascade also upregulates of proapoptotic genes by the phosphorylation of 
YAP and the phosphorylation of FOXO transcription factor. STK3 activity is decreased by 
the phosphatases (PP1 and PP2A) and Raf-1 and increased by RASSF1A, c-abl and its 
cleavage by caspase-3 which produces a constitutively active fragment that is resistant 
to dephosphorylation.  
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Figure 2.  STK3 is cleaved by caspase-3, 6 and 7. Brain lysate was 
incubated with serial dilutions of recombinant caspase-3, 6 or 7 
and analyzed by immonoblotting. The concentration of caspases 
from lane 1 to 9 are 0, 7.81, 15.63, 31.25, 62.5, 125, 250, 500 and 
1000 nM respectively. STK3 is cleaved by the all the executioner 
caspases albeit with varying efficacies (caspase-3 > caspase-7 > 
caspase-6). 
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Figure 3. STK3 mRNA expression levels in 
peripheral organs.  STK3 mRNA expression levels 
tends to decrease at 23-28 months of age in the 
liver (t test: 3 months vs.  23-28 months, p<0.05). In 
the kidney and the heart, STK3 mRNA decreases 
with aging (Kidney: ANOVA p=0.04, t test: 3 months 
vs.  12 months, p<0.05; 12 months vs. 23-28 
months, p<0.001; Heart: ANOVA p=0.02 post hoc: 3 
months vs. 30 months, p<0.01 ; t test: 12 months 
vs. >30 months, p<0.01). In contrast to the other 
peripheral organs, an increase of STK3 mRNA 
expression level is observed with the aging in the 
spleen(ANOVA p=0.009, post hoc: 3 months vs. 23-
28 months, p<0.01; 12 months vs. 23-28 months, 
p<0.05). n=5 by age-group. Tukey’s post hoc are 
presented on the graphs with a continuous line and  
t test are presented on the graphs with dotted line. 
. 
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Figure 4. Global increase of STK3 protein expression levels in peripheral tissues. A) The FL form of STK3, 
and the 34 kDa fragment increase in the liver with age (FL: t test: 3 months vs.  12 months, p<0.01; 12 
months vs. >30 months, p<0.05; 39 kDa: t test: 3 months vs. 12 months, p<0.05; 34 kDa: t test: 3 months 
vs. >30 months, p<0.05; 12 months vs. >30 months, p<0.05). B) No change in FL STK3 is observed in the 
kidney. In contrast, the STK3 39 kDa fragment increases in the kidney from 23-28 months of age (ANOVA 
p=0.0001, post hoc: 3 months vs.  23-28 months, p<0.01; 3 months vs. >30 months, p<0.001; 12 months 
vs. 23-28 months, p<0.01; 23-28 months vs. >30 months, p<0.001). C) No significant variation in STK3 
protein expression level is observed in the heart. However, an increasing linear trend is observed  in the 
34 kDa fragment (p=0.0255). D) No change in FL STK3 is observed in the spleen with age. However, STK3 
39 kDa and 34 kDa fragment expression level increase with aging in the spleen (39 kDa: t test: 3 months 
vs. 23-28 months, p<0.05; 3 months vs. >30 months, p<0.01; 34 kDa: t test: 3 months  vs. 12 months, 
p<0.05; 3 months  vs. >30 months, p<0.05). n=4 by age-group. Tukey’s post hoc are presented on the 
graphs with a continuous line and  t test are presented on the graphs with dotted line. 
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Figure  5. Global increase of STK3 mRNA 
expression levels in the brain STK3 mRNA 
expression increases initially then decreases 
with age in the cortex and the hippocampus 
(Cortex: ANOVA p=0.003, post hoc: 3 months vs.  
12 months, p<0.01; 12 months vs.  23-28 
months, p<0.05; 12 months vs.  >30 months, 
p<0.01; Hippocampus: ANOVA p<0.0001, post 
hoc: 3 months vs.  23-28 months, p<0.0001; 12 
months vs.  23-28 months, p<0.001; 23-28 
months vs.  >30 months, p<0.05). An increase in 
striatal STK3 mRNA expression level is observed 
with age. In contrast, no significant variation are 
observed in the cerebellum (Striatum: ANOVA 
p<0.0001, post hoc: 3 months vs.  23-28 months, 
p<0.0001; 12 months vs.  23-28 months, 
p<0.001; 12 months  vs. >30 months, p<0.05). 
n=5 by age-group. 
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Figure 6. Global increase of STK3 protein expression levels in the brain A,B) STK3 protein expression level 
increases in the cortex and the cerebellum with age (A (FL): ANOVA p=0.0006, post hoc: 3 months vs.  23-28 
months, p<0.01; 3 months vs. >30 months, p<0.001; 12 months vs. >30 months, p<0.01; A (34 kDa): ANOVA 
p=0.0002, post hoc: 12 months vs. 23-28 months, p<0.05; 3 months vs.  23-28 months, p<0.01; 3 months vs. 
>30 months, p<0.001; 12 months vs.  >30 months, p<0.01; B (FL): ANOVA p=0.0018, post hoc: 3 months vs.  23-
28 months, p<0.01; 3 months vs.  >30 months, p<0.05; 12 months vs. >30 months, p<0.05; 12 months vs.  >23-
28 months, p<0.05; B (34 kDa): t test: 3 months vs. 12 months, p<0.01; 12 months vs. >30 months, p<0.05). C) 
No significant variation is  observed in the FL form of STK3 in the striatum. However, the 34 kDa fragment 
tends to increase with age (ANOVA p=0.0509, r2=0.316 p=0.02). n=4 by age-group. Tukey post hoc are 
presented on the graphs. FL= full-length. 
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Figure  7. Overall caspase mRNA expression levels decrease in peripheral tissues with aging. A) 
Caspase 3 mRNA expression increases in the kidney and tends to decrease with aging in the heart 
(Kidney: ANOVA p=0.04, post hoc: 12 months vs. >30 months, p<0.05; Heart: t test: 12 months vs. >30 
months, p<0.01). No significant variation is observed in the liver and the spleen. B) Caspase-6 mRNA 
expression level decreases in the liver and the heart with age (Liver: ANOVA p=0.007, post hoc: 3 
months vs. 23-28 months, p<0.05; 3 months vs. >30 months, p<0.05; Heart: ANOVA p=0.005, post hoc: 
12 months vs. >30 months, p<0.01; 23-28 months vs. >30 months, p<0.05). In contrast, CASP6 mRNA 
tends to decrease at 12 months of age then increase at 23-28 months of age in the kidney (t test: 3 
months vs. 23-28 months, p<0.05; 12 months vs. >30 months, p<0.01). C) Caspase 8 mRNA expression 
decreases in the heart and a trend decrease is observed in the liver with age (Liver: 12 months vs. >30 
months, p<0.05; Heart: ANOVA p=0.015, post hoc: 3 months vs. >30 months, p<0.05; 12 months vs.  >30 
months, p<0.05). No significant variation in CASP8 mRNA is observed in the kidney and the spleen. n=5 
by age-group. Tukey’s post hoc are presented on the graphs with a continuous line and  t test are 
presented on the graphs with dotted line. # No Ct is detected for the 23-28 and >30 months group for 
CASP6. 
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Figure  8. Caspase protein expression levels vary with aging in peripheral organs. A, B, C, D) The p11 
caspase-3 fragment and caspase-6 proform decrease, all forms of caspase-8 increase and no signficant 
variation is observed with caspase 7 in the liver with aging (A (fragment): ANOVA p=0.03; B: t test: 12 
months vs. 23-28 months, p<0.05; D (proform): t test: 3 months vs. 23-28 months p<0.05; D (p43/41 ): t 
test: 3 months vs. 12 months p<0.001; 3 months vs. >30 months, p<0.01; D (p18): ANOVA p=0.03) E) In 
the kidney, the caspase-3 proform increases with age (ANOVA p=0.014) F, G, H, J, K, L) A global increase 
in caspase-6 and caspase-8 protein levels and a trend decrease in caspase-7 protein levels are observed 
in the kidney and the heart with  aging (F (Proform): ANOVA p<0.0001; F (p20p10): ANOVA p=0.0007; G 
(Proform): t test: 12 months vs >30 months, p=0.0502; 23-28 months vs >30 months, p=0.07; G (p27): t 
test: 12 months vs >30 months, p=0.0582; 23-28 months vs >30 months, p=0.053; H (proform): t test: 3  
months vs.  >30 months, p<0.05; H (p43/41): ANOVA p=0.0025; H (p18): ANOVA p=0.002; J (p20p10: 
ANOVA p=0.0146; K (Proform): 3 months vs. 12 months, p<0.05; L (proform): ANOVA p=0.0104; L 
(p43/41): ANOVA p=0.0037;  L (p18): p=0.002).  I, M) No significant variation is observed in caspase-3 
protein expression levels with aging in the heart and the spleen.  N, O) Caspase-6 protein expression 
level decrease in the spleen at 12 months of age (Proform: ANOVA, p=0.0501; t test: 3 months vs. 12 
months, p<0.05; t test: 3 months vs. >30 months,p<0.05; 12 months vs. >30 months, p<0.05; O (p27) 
and caspase-7 protein levels increase at >30 months of age (N (Proform): ANOVA, p=0.0516; t test: 3 
months vs. >30 months, p<0.05; 23-28 months vs. >30 months, p<0.05) P) Similar to the other 
peripheral organs, caspase-8 protein expression level increases with age in the spleen ( P (proform): t 
test: 3 months vs. 12 months p<0.05; 3 months vs. 23-28 months p<0.05; 3 months vs. >30 months 
p<0.05; P (p43/41): ANOVA p=0.003; P (p30): t test: 3 months vs. 12 months p<0.05; P (p18): t test: 3 
months vs. 12 months p<0.01). n=4 by age-group .Tukey’s post hoc are presented on the graphs. 
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Figure  9. Caspase 6 activity increases in the liver and kidney and Caspase 8 activity increase with 
aging in the kidney, heart and spleen.  A) A trend increase is observed in CASP3/7 activity in the liver (t 
test: 3 months vs. >30 months, p<0.01; 12 months vs. >30 months, p<0.01.). No significant variation is 
observed in CASP6 and 8 activity B) In the kidney, CASP3/7 activity increase at 23-28 months of age (t 
test: 12 months vs. 23-28 months , p<0.05). Caspase 8 activity decrease at 12 months and increases at 
>30 months (ANOVA p=0.03, post hoc: 3 months vs. 12 months, p<0.05; t test: 12 months vs. >30 
months, p<0.0001). C) An increase is observed  in the heart in CASP6 and 8 activity with aging (CASP6: t 
test: 23-28 months vs. >30 months, p<0.05; CASP8: t test: 3 months vs. 23-28 months, p<0.05; 3 months 
vs.  >30 months, p<0.05). No significant variation is observed in CASP3/7 with aging in the heart. D) 
Caspase 8 activity increases with aging in the spleen (t test: 3 months vs.  23-28 months, p<0.05; 3 
months vs. >30 months, p<0.05). No significant variation is observed in the spleen for CASP3/7 and 6 
activity with aging. n=4 by age-group. Tukey’s post hoc are presented on the graphs with lines and t test 
are presented using dotted lines. 
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Figure  10. Caspase-6 mRNA expression increases in the striatum and hippocampus with age.  A) 
Caspase 3 mRNA expression decrease in the cortex and the hippocampus with age (Cortex: ANOVA 
p=0.0103, post hoc: 3 months vs. >30 months, p<0.05; 12 months vs. >30 months, p<0.05; 
Hippocampus: t test: 3 months vs. >30 months, p<0.05; 12 months vs. >30 months, p<0.01). No 
significant variation is observed in CASP3 mRNA expression in the cerebellum and the striatum. B) In the 
cortex, caspase-6 mRNA expression decreases at 23-28 months of age (ANOVA p=0.04, post hoc: 12 
months vs. 23-28 months, p<0.05). In contrast, caspase-6 mRNA expression increases in the striatum 
and the hippocampus (Striatum: ANOVA p=0.0005, post hoc: 3 months vs.  23-28 months, p<0.01; 12 
months vs.  23-28 months, p<0.001; 23-28 months vs. >30 months, p<0.05; Hippocampus: ANOVA 
p=0.007, post hoc: 3 months vs. >30 months, p<0.01) No significant variation is observed in the 
cerebellum. C) Caspase 8 mRNA expression tends to decrease at >30 months of age in the cortex. In 
contrast, an increase in CASP8 mRNA expression is observed in the cerebellum and the striatum 
(Cerebellum: ANOVA p=0.0589, t test: 12 months vs..  >30 months, p<0.001; Striatum: t test: 12 months 
vs. >30 months, p<0.05). n=5 by age-group . Tukey’s post hoc are presented on the graphs with a 
continuous line and  t test are presented on the graphs with dotted line. 
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Figure  11. Global increase in caspases protein expression level in the brain with the aging A, B, C, D) 
Caspase-3 do not vary with age in the striatum whereas caspase-6 tends to decrease and caspase-7 and 
-8 increase with aging (B (proform) : t test: 3 months vs. 23-28 months; C (Proform): r2=0.29, p=0.04; D 
(proform): ANOVA p=0,007; D(p30) : ANOVA p=0.007; D (p18) : t test: 3 months vs. 12 months, p<0.01). 
E ,F ,H) Caspase-3, 6 and 8 expression increases or tends to increase with age in the cortex (E (proform): 
t test:  3 months vs.  12 months, p<0.5; 3 months vs. >30 months, p<0.5; F (p20p10): t test: 3 months vs. 
12 months, p<0.5; 3 months vs. >30 months, p<0.5; H (proform): ANOVA p=0.009; H (p43/41): ANOVA 
p=0.004; H (p30) : ANOVA p=0,013; H (p18) : t test 3 months vs. 23-28 months p<0,05). G, K) No 
significant variation is observed in caspase-7 protein expression level in the cortex and cerebellum. I, J, 
L) Caspase-6 and 8 expression increases or tends to increase with age in the cerebellum whereas 
caspase-3 decreases with aging (I (proform): t test: 3 months vs. >30 months, p<0.05; 12 months vs. >30 
months, p<0.05; I (30 kDa): ANOVA p=0.03; J (proform): ANOVA p=0.013; L (proform): t test: 3 months 
vs. >30 months, p<0.05; L (p43/41): t test: 3 months vs. >30 months, p<0.05). n=4 by age-group.Tukey’s 
post hoc are presented on the graphs. 
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Figure 12. Caspase-6 activity increases in the cortex with aging. A) No significant variation in caspases 
activty is observed with aging in the cerebellum. B) Caspase-6 increase while CASP8 activity tends to 
decrease in the cortex with aging (Caspase 6: ANOVA p=0.02, post hoc : 3 months vs. 23-28 months, 
p<0.05 ; Caspase 8: t test: 12 months vs. >30 months ) No significant variation is observed in CASP3 
activity. n=4 by age-group. Tukey’s post hoc are presented on the graphs with a continuous line and  t 
test are presented on the graphs with dotted line. 
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Table 1. Summary table of the age associated variation in STK3 and caspases expression and activity. 
*Analysis of CASP3 and CASP7 activity by the same peptide. Pro = Proform, FL = Full-lenght, p20p10 = 
CASP6 without the prodomain.  
 
 
 
 
 
 
 
 
 
 
RNA FL 39 kDa 34 kDa RNA Pro p30 p19/p17 *Activity RNA Pro p20p10 Activity Pro p27 p20 *Activity RNA Pro p43/41 p30 p18 Activity
Liver ↓ ↓↑ ↓ ↑  -  - ↑ ↓ ↓  -  -  - ↑ ↓ ↑ ↑ ↑  -
Kidney ↓  - ↑  - ↑ ↑ ↓ ↑ ↓↑ ↑ ↑  - ↓ ↓ ↑  - ↑ ↑ ↑ ↓↑
Heart ↓  -  - ↓  -  - ↓  - ↑ ↑ ↓  - ↓ ↑ ↑ ↑ ↑ ↑
Spleen ↑  - ↑ ↑  -  -  -  - ↓  -  - ↑  -  -  - ↑ ↑ ↑ ↑ ↑
Cortex ↑↓ ↑ ↑ ↓ ↑  -  -  - ↓  - ↑ ↑  -  -  - ↓ ↑ ↑ ↑ ↑ ↓
Cerebellum ↑ ↑ ↓↑  - ↓ ↓ ↓  -  - ↑  -  -  -  - ↑ ↑ ↑  -  -  -
Striatum ↑  -  -  -  -  - ↑↓ ↓  - ↑ ↑ ↑↓  - ↑ ↑
Hippocampus ↑↓ ↓ ↑  -
STK3 Caspase 6 Caspase 8Caspase 3 Caspase7
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Supplementary figure 1. Western blot of STK3, CASP3, CASP6, 
CASP7 and CASP8 in the liver. A) An example of STK3, CASP3, 
CASP6, CASP7 and CASP8 immunoblot is presented of liver samples. 
The protein loading reference is the Coomassie blue staining for all 
the peripheral organs. 
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Supplementary figure 2. Western blot of STK3, CASP3, CASP6 , 
CASP7 and CASP8 in the kidney A) An example of STK3, CASP3, 
CASP6, CASP7 and CASP8 immunoblot is presented of kidney 
samples. The protein loading reference is the Coomassie blue 
staining for all the peripheral organs. 
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Supplementary figure 3. Western blot of STK3, CASP3, CASP6 , 
CASP7 and CASP8 in the heart A) An example of STK3, CASP3, 
CASP6, CASP7 and CASP8 immunoblot is presented of heart 
samples. The protein loading reference is the Coomassie blue 
staining for all the peripheral organs. 
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Supplementary figure 4. Western blot of STK3, CASP3, CASP6 , 
CASP7 and CASP8 in the spleen A) An example of STK3, CASP3, 
CASP6, CASP7 and CASP8 immunoblot is presented of spleen 
samples. The protein loading reference is the Coomassie blue 
staining for all the peripheral organs. 
38
Supplementary figure 5 Western blot of STK3, CASP3, CASP6, 
CASP7 and CASP8 in the cortex. A) An example of STK3, CASP3, 
CASP6, CASP7 and CASP8 immunoblot is presented of cortex 
samples. The protein loading reference calnexin and actin were 
assessed in  all brain regions. 
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Supplementary figure 6. Western blot of STK3, CASP3, CASP6 , 
CASP7 and CASP8 in the cerebellum. A) An example of STK3, 
CASP3, CASP6, CASP7 and CASP8 immunoblot is presented of 
cerebellum samples. The protein loading reference calnexin and 
actin were assessed in  all brain regions. 
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Supplementary figure 7. Western blot of STK3, CASP3, CASP6 , 
CASP7 and CASP8 in the striatum. A) An example of STK3, CASP3, 
CASP6, CASP7 and CASP8 immunoblot is presented of striatum 
samples. The protein loading reference calnexin and actin were 
assessed in  all brain regions. 
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